ライフサイエンスコーパス: IVR

1 ered from intravaginal rings, we designed an IVR that contains a drug matrix encapsulated in the core

2 s in safety outcomes between IVT-AFL 2q8 and IVR 0.5 mg PRN or dexamethasone 0.7 mg implants.

3 ferential between PRP and IVR increases, and IVR therapy may exceed the typical accepted limit of cos

4 etime, the cost differential between PRP and IVR increases, and IVR therapy may exceed the typical ac

5 The BACK/IVR domains of ARA3 also are sufficient to modify AHR si

6 nslocator/simple-minded) domain and the BACK/IVR domains of ARA3 mediate the AHR-ARA3 interaction.

7 edistribution (IVR) and the relation between IVR and molecular structure.

8 nvariant glycine 56 and a strongly conserved IVR, whereas nonaxonemal beta-tubulins vary widely in IV

9 Conversely, during IVR, flow was initially directed toward the apex and the

10 e 3 apical views, and SR was measured during IVR (SR(IVR)) and early LV filling (SR(E)).

11 However, whether the effective IVR dimensionality can vary with time and whether the me

12 The elastomeric IVR body (matrix) was produced by hot melt extrusion of

13 system, even above the threshold for facile IVR.

14 eas nonaxonemal beta-tubulins vary widely in IVR sequences.

15 Secondary end points included IVR-reported changes in pain, weakness, and tiredness; c

16 intramolecular motions and thus inefficient IVR.

17 stical rate theories, assuming instantaneous IVR, predict exponential decay of the population with th

18 otein exocytosis was enhanced by ivermectin (IVR).

19 hH4v is on LG IVR and the hH2A-hH2B pair is located immediately right

20 rate proof-of-concept of a novel core-matrix IVR for sustained and simultaneous delivery of diverse m

21 The MZCL IVR contains four active pharmaceutical ingredients (API

22 ore-matrix intravaginal ring (IVR), the MZCL IVR, which effectively delivered the MZC combination mic

23 At baseline, 18 of 28 animals had negative IVR(SR) (i.e., PSS) in at least one segment.

24 During coronary artery occlusion, IVR(SR) became negative and larger in magnitude than S(S

25 text have come from the state space model of IVR, which predicts power law behavior for the rates wit

26 Deuteration increases the rate of IVR, which decreases the fraction of recrossing and incr

27 ual acuity measures compared with studies of IVR 0.5 mg PRN and dexamethasone 0.7 mg implants based o

28 d visual acuity (BCVA) with IVT-AFL 2q8 over IVR 0.5 mg PRN by 4.67 letters [95% credible interval (C

29 sotropic and anomalous nature of the quantum IVR dynamics and show that multiple power law scalings d

30 IVT-AFL 2q8 versus intravitreal ranibizumab (IVR) 0.5 mg as needed (PRN) (10 studies) and IVT-AFL 2q8

31 molecular vibrational energy redistribution (IVR) and the relation between IVR and molecular structur

32 molecular vibrational energy redistribution (IVR) effects.

33 molecular vibrational energy redistribution (IVR) is at the heart of chemical reaction dynamics.

34 molecular vibrational energy redistribution (IVR) is indicated through the extensive local perturbati

35 y intramolecular vibrational redistribution (IVR) from the pumped rotational mode to all others.

36 f intramolecular vibrational redistribution (IVR) in p-benzyne is too slow to prevent this.

37 h" (BACK) domain, and an intervening region (IVR).

38 n the beta-tubulin internal variable region (IVR).

39 R ratio during the isovolumetric relaxation (IVR) period can be used to estimate LV filling pressures

40 ring systole (S(SR)), isovolumic relaxation (IVR(SR)), and rapid filling (E(SR)) phases in both ische

41 contraction (IVC) and isovolumic relaxation (IVR) might represent a transient feature of myocardial w

42 Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenof

43 s recorded on an interactive voice response (IVR) diary (scale of 1 = minimal to 9 = worst ever exper

44 polyether urethane (HPEU) intravaginal ring (IVR) for sustained delivery of the anti-HIV agent tenofo

45 cribe a novel core-matrix intravaginal ring (IVR), the MZCL IVR, which effectively delivered the MZC

46 SR(IVR) had a strong correlation with time constant of LV p

47 E/SR(IVR) can predict LV filling pressures with reasonable ac

48 n and echocardiographic imaging, mitral E/SR(IVR) ratio had the best correlation with mean wedge pres

49 E/SR(IVR) was most useful in patients with ratio of E to mitr

50 Global SR(IVR) by 2-dimensional speckle tracking is strongly depen

51 al views, and SR was measured during IVR (SR(IVR)) and early LV filling (SR(E)).

52 All TDF IVR-treated macaques (n = 6) remained seronegative and s

53 Cost utility for PRP would be 85% lower than IVR in the facility setting and 90% lower than IVR in th

54 R in the facility setting and 90% lower than IVR in the nonfacility setting.

55 However, there is growing evidence that IVR competes with the reaction timescales, resulting in

56 transition state theory, which suggests that IVR in this reaction can be studied by conventional KIEs

57 The IVR(SR)/S(SR) and epsilon(ps) best differentiated ischem

58 ime constant of LV pressure decay during the IVR period (tau) (r=-0.83, P<0.001), whereas SR(E) was s

59 ng a measure of the nature and extent of the IVR dynamics.

60 drug matrix encapsulated in the core of the IVR whereby the mechanism of drug release is uncoupled f

61 ent-reported severity score stiffness on the IVR diary.

62 was released by diffusion via a pore on the IVR while the MIV-150/LNG diffused from the matrix conti

63 The fact that the IVR process produces isomerization is deduced through a

64 solid hydrophilic core, embedded within the IVR by compression, contained the small molecule ZA and

65 pH 4.2 for 30 or 90 days, during which times IVR mechanical properties and swelling kinetics were mon

66 When IVR was the primary treatment, the 2-year cost in the fa

67 PRP treatment of $14 219 to $24 005 and with IVR of $138 852 to $164 360.

68 PRP compared with IVR as primary treatment for PDR is less expensive over